Analysis of patient-reported experiences up to 2 years after receiving idecabtagene vicleucel (ide-cel, bb2121) for relapsed or refractory multiple myeloma: Longitudinal findings from the phase 2 KarMMa trial

  1. Delforge, M.
  2. Otero, P.R.
  3. Shah, N.
  4. Moshkovich, O.
  5. Braverman, J.
  6. Dhanda, D.S.
  7. Lanar, S.
  8. Devlen, J.
  9. Miera, M.
  10. Gerould, H.
  11. Campbell, T.B.
  12. Munshi, N.C.
Revista:
Leukemia Research

ISSN: 1873-5835,  0145-2126

Ano de publicación: 2023

Volume: 129

Tipo: Artigo

DOI: 10.1016/J.LEUKRES.2023.107074 GOOGLE SCHOLAR lock_openAcceso aberto editor
Fonte de datos: Scopus